Table 1.
Patient study groups and their characteristics
| Classification | Training set cut-off study group |
Validation set study group |
Clinical analysis study group |
|||
|---|---|---|---|---|---|---|
| n = 60 | % | n = 145 | % | n = 205 | % | |
| Age, years | ||||||
| <50 | 31 | 51.7 | 57 | 39.3 | 88 | 42.9 |
| ≥50 | 29 | 48.3 | 88 | 60.7 | 117 | 57.1 |
| T stage | ||||||
| T1 | 24 | 40.0 | 75 | 51.7 | 99 | 48.3 |
| T2, T3, T4, Tx | 36 | 60.0 | 70 | 48.3 | 106 | 51.7 |
| N stage | ||||||
| N1 | 45 | 75.0 | 110 | 75.9 | 155 | 75.6 |
| N2 | 13 | 21.7 | 34 | 23.4 | 47 | 22.9 |
| N3 | 2 | 3.3 | 1 | 0.7 | 3 | 1.5 |
| Grading G | ||||||
| G1 | 0 | 0.0 | 9 | 6.2 | 9 | 4.4 |
| G2 | 38 | 63.3 | 100 | 69.0 | 138 | 67.3 |
| G3 | 22 | 36.7 | 36 | 24.8 | 58 | 28.3 |
| Lymph nodes involved, n | ||||||
| 1–3 | 37 | 61.7 | 94 | 64.8 | 131 | 63.9 |
| >3 | 23 | 38.3 | 51 | 35.2 | 74 | 36.1 |
| ER positivity | 60 | 100 | 145 | 100 | 205 | 100 |
| HER2 negativity | 60 | 100 | 145 | 100 | 205 | 100 |
| Endocrine therapy | ||||||
| Yes | 41 | 68.3 | 99 | 68.3 | 140 | 68.3 |
| No | 19 | 31.7 | 46 | 31.7 | 65 | 31.7 |
| Disease recurrence | ||||||
| Yes | 31 | 51.7 | 74 | 51.0 | 105 | 51.2 |
| No | 29 | 48.3 | 71 | 49.0 | 100 | 48.8 |
| Disease recurrence (plus ET) | ||||||
| Yes | 18 | 30.0 | 43 | 29.7 | 61 | 29.8 |
| No | 23 | 38.3 | 56 | 38.6 | 79 | 38.5 |
| Overall survival | ||||||
| Yes | 23 | 38.3 | 50 | 34.5 | 73 | 35.6 |
| No | 37 | 61.7 | 95 | 65.5 | 132 | 64.4 |
| Radiotherapy | ||||||
| Yes | 42 | 70.0 | 106 | 73.1 | 148 | 72.2 |
| No | 18 | 30.0 | 39 | 26.9 | 57 | 27.8 |
| PMR (cut-off) | ||||||
| ≤12 | 41 | 68.3 | 102 | 70.3 | 143 | 69.8 |
| >12 | 19 | 31.7 | 43 | 29.7 | 62 | 30.2 |
ER = Estrogen receptor, HER2 = human epidermal growth factor receptor 2, ET = endocrine therapy, PMR = percent DNA methylation ratio.